Moderate and Severe TBI requires an agent to reduce ICP....

Moderate and Severe TBI requires an agent to reduce ICP. Presendin or a GLP-1 would be the first proven medication that could do this with an unencumbered TAM. Problem is that the timeline will stretch out for another 7-10 years to get a drug candidate to market, so more likely to see Pharma take control to run the long game than the current Invex team. David M and Tattarang will be looking for the highest bidder now.

And the point by Jellyroll is crucial. This is Sinclair's lifework. She holds 2 million shares alongside options. She will want to see a return from Invex in some capacity. And if it's big pharma who buy it out, then she can consult with them to run IIH EVOLVE trial to completion.